IMPORTANCE Clinical genomic tests that examine the DNA sequence of large numbers of genes are commonly used in the diagnosis and management of epilepsy in pediatric patients. The reported variants resulted in 61 patients with and 124 patients without a genetic diagnosis (VUS variants only). On reinterpretation of all reported variants, 67 of the 185 patients (36.2%) had a change in variant classification. Of the 67 patients with a genetic variant change in interpretation, 21 (31.3%) experienced a change in diagnosis. During the 5 years of the study, 19 of 61 patients (31.1%) with a genetic diagnosis and 48 of 124 patients (38.7%) with undiagnosed conditions (VUS only) had their results reclassified. Review of genomic reports issued during the final 2 years of the study identified reclassification of variants in 4 of 16 patients (25.0%) with a pathogenic or likely pathogenic variant and 11 of 41 patients (26.8%) with a VUS.
G enomic testing is used to evaluate many pediatric neurologic diseases, including intractable epilepsy and neuromuscular disorders. A recent study 1 3, 4 However, no clear recommendations guide the frequency of review of previously issued laboratory diagnoses. Current clinical genomic tests include disease-specific panels, whole exome sequencing, and whole genome sequencing, which are powerful tools when used in combination with clinical knowledge. 5 Recent reports 6, 7 have focused on the discovery and identification of new disease associations by reanalysis of genomic data. Only a few genomic studies [8] [9] [10] [11] have expanded the scope of reanalysis to include all gene variants previously reported. In a recent genomic reanalysis study 8 was initially reported. Thirty-five patients had both a VUS and a P-LP variant reported. After reanalyzing all cases with reported variants from the past 5 years, 67 of the 185 patients (36.2%) with a reported gene variant had a revised classification. A clinically significant change in diagnosis occurred in 21 of the 185 patients (11.4%) ( Figure 1 ). Nineteen P-LP variants were downgraded in pathogenicity (14 to VUS and 5 to B-LB), and 2 VUSs were upgraded to P-LP (Table) . Nine of these 21 reclassified variants were in concordance with the original laboratory data in upgraded or downgraded significance as reported in ClinVar and/or the patient's updated medical record.
Next, we examined the likelihood of reclassification over time. The reclassification rates for patients with P-LP variants and VUSs were similar, with nonsignificant differences in slope (P-LP, 6% change per year; VUS, 9% change per year; P = .24) ( Figure 1 ). In total, 19 of 61 patients (31.1%) had a change
Key Points Question How often do genomic test result interpretations change?
Findings In this study of reported genetic variants from clinical genomic epilepsy tests, 67 of 185 pediatric patients (36.2%) had variants reclassified. A clinically significant change in the interpretation occurred in 19 of 61 patients (31.1%) with a genetic diagnosis during the 5-year study.
Meaning The findings of this study suggest that pediatric patients with epilepsy and previous genomic test results should have their test results reinterpreted at least every 2 years and before further genetic testing.
in genetic diagnosis. Examination of a subset of the most recent 2 years of data identified 4 of 16 P-LP variants (25.0%) and 11 of 41 VUSs (26.8%) as reclassified.
The most frequently downgraded P-LP variants were missense (n = 13) (Figure 2) . In most cases, protein-truncating vari- (Figure 2 ). Many of the downgraded P-LP variants or VUSs were similarly downgraded by the original reporting laboratory as observed in the laboratory's ClinVar and/or medical record updates. Of the 124 patients with no definitive diagnosis (VUS only), 2 (1.6%) had a VUS upgraded to P-LP (Table) ; however, 46 of 124 patients (37.1%) had their variants downgraded to B-LB. Most reclassified VUSs were missense variants (n = 62) followed by synonymous or deletion variants (Figure 2 
Discussion
On the basis of our single institution experience, 67 of 185 patients (36.2%) had revised gene variant interpretations. A clinically significant change in diagnosis occurred for 21 patients (11.4%). During the 5-year study period, patients with P-LP variants had a yearly reclassification rate of 5.5% and patients with VUSs had a yearly reclassification rate of 8.7%. This change in reclassification affected 19 of 61 patients (31.1%) with a P-LP variant and 48 of 124 patients (38.7%) with a VUS. In the final 2 years of the study, 4 of 16 patients (25.0%) with a P-LP variant and 11 of 41 patients (26.8%) with a VUS were affected.
Compared with the 36.2% variant reclassification rate observed in this study, another recent study 8 that examined changes to P-LP variants and VUSs found a lower rate of reclassification (6%; 23 patients with variants upgraded in significance and 6 patients with variants downgraded in significance). The difference in the rate of reclassification may be because of the longer period of review in our study (5 years) compared with the previous study 8 (2 years). Of more importance, the previous study 8 examined patients with intellectual disability and/or developmental delay, whereas our study was focused on pediatric patients with epilepsy. We anticipate that both the patient's disease and the passage of time will influence the degree to which reinterpretation will occur. We recommend that reinterpretation of genetic test results for pediatric patients with epilepsy be performed at a minimum frequency of every 2 years. The reinterpretation should not be limited to genomic tests but should include all previously reported genetic tests. Before the initiation of the study, we had anticipated that the variants requiring reclassification might decrease after the publication of the 2015 ACMG guidelines 4 or the . The most frequently downgraded P-LP variant type was missense (n = 13) followed by protein truncating variants (structural, n = 3; stop-loss, n = 2) and duplications (n = 1). For VUS types that changed, the most frequent type was missense (n = 62) followed by synonymous (n = 2) and deletions (n = 1 release of population databases in 2014. 15 On the contrary, the pattern of reclassifications was unchanged.
Limitations
This study was limited by an absence of an analysis of B-LB variants that may be upgraded to P-LP variants or VUSs; these variants were unavailable for examination. In addition, we used a consensus interpretation approach and did not examine variations in interpretation among health care professionals; however, this was mitigated by our frequent positive correlation (9 of 21), with upgraded and downgraded interpretations posted by the original laboratory to ClinVar and/or patient's medical record (Table) . Also, it is possible that our reinterpretation of variants in this study may not have included all of the evidence available in the literature.
Conclusions
This study suggests that clinical laboratories should commit to reinterpretation of P-LP variants and VUSs, and corrected laboratory reports should be communicated to treating physicians. Furthermore, physicians should understand and communicate to patients that medical knowledge is dynamic and genetic test interpretations may change over time. In summary, patients with previous epilepsy genomic test results should have their test results reinterpreted at least every 2 years and before further genetic testing. Applying these recommendations to other genomic tests is worth considering and should be investigated in future studies.
